Sep 13, 2023 / 06:00PM GMT
Catherine Walden Ramsey Schulte - Robert W. Baird & Co. Incorporated, Research Division - Senior Research Analyst
All right, great. I'm Catherine Schulte. I cover life sciences and diagnostics here at Baird. Very excited to have QIAGEN here joining us today. From the company, we have the CEO, Thierry Bernard. So thanks so much for joining us.
Thierry Bernard - Qiagen N.V. - CEO, MD & Member of Management Board
Thank you, and thanks for your attention and interest in QIAGEN. Thanks.
Questions and Answers:
Catherine Walden Ramsey Schulte - Robert W. Baird & Co. Incorporated, Research Division - Senior Research AnalystAnd we're going to dive right into Q&A. So if anyone from the audience has any questions, you can send it to [email protected], and I will pass it along.
So maybe to kick things off, just talk about your outlook for '23. I think the back half of the year, guidance implies 6% CER growth, which is markedly better than what we're seeing peers with instrumentation headwinds,
Trustpilot
